Teva closes in on sale of API business TAPI0 SHARESPosted: 2 October 2025 | Dominic Tyer (European Pharmaceutical Review) |The pharma company’s plan to divest its active pharmaceutical ingredient interests was first announced in 2024. The road ahead for Teva’s active pharmaceutical ingredient (API) business has become a little clearer, with the company confirming it is in “advanced discussions” about TAPI’s sale. That was followed by Teva’s decision in January 2024 to divest the TAPI business altogether and it has been up for sale ever since. Teva’s planned sale of its TAPI business comes amid a ramping up of pressure from the US for pharma to increase its domestic API production and API investments from Lilly in Virginia and Texas and from AbbVie in Illinois. Even before this year’s hardening of an America-first economic agenda from the US, Teva had previously issued multiple warnings over risks to API manufacturing in Europe.